Copyright (c) 2009 Yahoo! Inc. All rights reserved.http://finance.yahoo.com/q/h?s=osipLatest Financial News for OSI Pharmaceuticals Inc.en-usTue, 29 Dec 2009 22:47:40 Etc/GMThttp://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gifhttp://finance.yahoo.com14417http://us.rd.yahoo.com/finance/external/reuters/rss/SIG=118cks9u6/*http%3A//www.reuters.com/legacyArticle?duid=mtfh26618_2009-12-29_22-47-40_n29198801_newsml&rpc=44&type=marketsNewsyahoo_finance/3728273583Tue, 29 Dec 2009 22:47:40 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/mp#osipyahoo_finance/3064179600Tue, 29 Dec 2009 15:01:48 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091229/20091229005248.html?.v=1MELVILLE, N.Y.----OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office has granted reissue patent RE41,065, replacing Tarceva’s® composition of matter patent .yahoo_finance/3151376882Tue, 29 Dec 2009 15:01:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/mfool/rss/SIG=12mfocskg/*http%3A//www.fool.com/investing/general/2009/12/28/4-star-stocks-on-the-upswing.aspx?source=eptyholnk303100&logvisit=y&npu=yyahoo_finance/16404535Mon, 28 Dec 2009 19:50:32 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/zacks/091223/28601.html?.v=1yahoo_finance/3340341734Wed, 23 Dec 2009 12:24:01 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/091222/us_osi_pharmaceuticals_outlook.html?.v=1OSI Pharmaceuticals Inc. on Tuesday trimmed its 2010 revenue outlook citing a potential regulatory roadblock to the cancer drug Tarceva. However, the drug developer still expects growth of 10 percent or more in adjusted earnings per share.yahoo_finance/366727960Tue, 22 Dec 2009 13:09:14 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091222/20091222005313.html?.v=1MELVILLE, N.Y.----OSI Pharmaceuticals, Inc. today provided an update to the preliminary revenue and adjusted earnings per share growth rate guidance provided to investors at the Company’s recent analyst R&D day meeting on December 3, 2009.yahoo_finance/2018786305Tue, 22 Dec 2009 12:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/zacks/091218/28477.html?.v=1OSIP announced that the advisory panel of the FDA did not recommend the additional usage of its lung cancer drug Tarceva.yahoo_finance/1315872549Fri, 18 Dec 2009 15:46:06 Etc/GMThttp://us.rd.yahoo.com/finance/external/cbsm/rss/SIG=12lfee3o2/*http%3A//www.marketwatch.com/news/story/drug-stocks-chase-broader-market/story.aspx?guid=%7B3C29A466%2D7B7F%2D4E21%2D99C0%2D4E6C04B8EB78%7D&siteid=yhoofOSI Pharmaceuticals leads the downward trend for the larger-cap biotech issues after a setback for its lung-cancer drug.yahoo_finance/713624431Thu, 17 Dec 2009 20:33:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/pssa/rss/SIG=12eret359/*http%3A//seekingalpha.com/article/178716-lilly-to-benefit-from-osi-rejection?source=yahooyahoo_finance/637918994Thu, 17 Dec 2009 19:04:36 Etc/GMThttp://us.rd.yahoo.com/finance/external/bizj/rss/SIG=128ciqh1j/*http%3A//boston.bizjournals.com/boston/stories/2009/12/14/daily49.html?ana=yfcpcyahoo_finance/71144361Thu, 17 Dec 2009 16:05:23 Etc/GMThttp://us.rd.yahoo.com/finance/external/cbsm/rss/SIG=12gd01k26/*http%3A//www.marketwatch.com/news/story/drug-stocks-slip-osi-slides/story.aspx?guid=%7B3C29A466%2D7B7F%2D4E21%2D99C0%2D4E6C04B8EB78%7D&siteid=yhoofOSI Pharmaceuticals led the downward trend for the larger-cap biotech issues after a setback for its lung-cancer drug.yahoo_finance/3278125306Thu, 17 Dec 2009 15:16:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/wsj/rss/SIG=12iurgta1/*http%3A//online.wsj.com/article/SB10001424052748704541004574600332619143404.html?ru=yahoo&mod=yahoo_hsyahoo_finance/3563005698Thu, 17 Dec 2009 02:26:56 Etc/GMThttp://us.rd.yahoo.com/finance/external/reuters/rss/SIG=118cks9u6/*http%3A//www.reuters.com/legacyArticle?duid=mtfh06389_2009-12-16_22-35-43_n16120718_newsml&rpc=44&type=marketsNewsyahoo_finance/52691136Wed, 16 Dec 2009 22:35:43 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/091216/us_fda_osi_pharma.html?.v=7Federal health advisers on Wednesday recommended against expanding approval of an OSI Pharmaceuticals lung cancer drug to patients who are already responding to chemotherapy.yahoo_finance/2039513600Wed, 16 Dec 2009 22:31:31 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091216/20091216006216.html?.v=1MELVILLE, N.Y.----OSI Pharmaceuticals, Inc. announced today that the Company will host a live conference call Thursday, December 17, at 8:30 AM Eastern Time to discuss the Oncologic Drug Advisory Committee panel’s review of the supplemental New Drug Application for use of Tarceva® as first-line maintenance therapy for patients with advanced or metastatic non-small cell lung cancer whose cancer has not progressed following first-line treatment with platinum-based chemotherapy.yahoo_finance/2579113698Wed, 16 Dec 2009 21:50:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091216/20091216006210.html?.v=1GAITHERSBURG, Md.----OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group , announced today that the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee voted 12 to one recommending against approval of the daily pill Tarceva® for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer whose cancer has not progressed following first-line treatment with platinum-based chemotherapy.yahoo_finance/2432420008Wed, 16 Dec 2009 21:40:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/reuters/rss/SIG=118cks9u6/*http%3A//www.reuters.com/legacyArticle?duid=mtfh76709_2009-12-15_00-11-49_n14175293_newsml&rpc=44&type=marketsNewsyahoo_finance/221578124Tue, 15 Dec 2009 00:11:49 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/ap/091214/us_osi_pharma_cancer_drug.html?.v=6Federal health regulators say OSI Pharmaceutical's Tarceva slows the progression of lung cancer and extends patients' lives when used as a follow-up to chemotherapy.yahoo_finance/3090119813Mon, 14 Dec 2009 18:40:33 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091204/osip8-k.htmlyahoo_finance/3666246813Fri, 4 Dec 2009 18:24:33 Etc/GMT